SV2017005587A - Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen - Google Patents

Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen

Info

Publication number
SV2017005587A
SV2017005587A SV2017005587A SV2017005587A SV2017005587A SV 2017005587 A SV2017005587 A SV 2017005587A SV 2017005587 A SV2017005587 A SV 2017005587A SV 2017005587 A SV2017005587 A SV 2017005587A SV 2017005587 A SV2017005587 A SV 2017005587A
Authority
SV
El Salvador
Prior art keywords
hydroxiester
derivatives
preparation
new
pharmaceutical compositions
Prior art date
Application number
SV2017005587A
Other languages
English (en)
Inventor
Soltan Szlávik
András Kotschy
Maïa Chanrion
Didier Demarles
Olivier Geneste
James Edward Paul Dadvison
James Murray Broke
Szaboles Sipos
Attila Paczal
Baláks Bálint
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of SV2017005587A publication Critical patent/SV2017005587A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DE FÓRMULA (1): (VER FORMULA) EN LA QUE R1, R2, R3, R4, R5, R6, R7, R13, RA, RB, A Y N SON COMO SE HAN DEFINIDO EN LA DESCRIPCIÓN
SV2017005587A 2015-06-23 2017-12-12 Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen SV2017005587A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1555752A FR3037957B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
SV2017005587A true SV2017005587A (es) 2018-04-11

Family

ID=54608634

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005587A SV2017005587A (es) 2015-06-23 2017-12-12 Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen

Country Status (44)

Country Link
US (2) US10227358B2 (es)
EP (1) EP3313851B1 (es)
JP (1) JP6741697B2 (es)
KR (1) KR20180019223A (es)
CN (1) CN107709333B (es)
AR (1) AR105103A1 (es)
AU (1) AU2016282836B2 (es)
BR (1) BR112017027414B1 (es)
CA (1) CA2990088C (es)
CL (1) CL2017003258A1 (es)
CO (1) CO2017012786A2 (es)
CR (1) CR20170564A (es)
CU (1) CU20170160A7 (es)
CY (1) CY1122542T1 (es)
DK (1) DK3313851T3 (es)
EA (1) EA033266B1 (es)
EC (1) ECSP17081744A (es)
ES (1) ES2759480T3 (es)
FR (1) FR3037957B1 (es)
GE (1) GEP20207074B (es)
HK (2) HK1249506A1 (es)
HR (1) HRP20200107T1 (es)
HU (1) HUE047889T2 (es)
IL (1) IL256270A (es)
JO (1) JO3675B1 (es)
MA (1) MA42239B1 (es)
MD (1) MD3313851T2 (es)
MX (1) MX2017016997A (es)
MY (1) MY190561A (es)
NZ (1) NZ738455A (es)
PE (1) PE20180742A1 (es)
PH (1) PH12017502246B1 (es)
PL (1) PL3313851T3 (es)
PT (1) PT3313851T (es)
RS (1) RS59904B1 (es)
RU (1) RU2734418C2 (es)
SI (1) SI3313851T1 (es)
SV (1) SV2017005587A (es)
TN (1) TN2017000511A1 (es)
TW (1) TWI604844B (es)
UA (1) UA122228C2 (es)
UY (1) UY36736A (es)
WO (1) WO2016207225A1 (es)
ZA (1) ZA201708460B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI759316B (zh) 2016-07-22 2022-04-01 法商施維雅藥廠 Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
WO2018126898A1 (zh) * 2017-01-05 2018-07-12 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
MX2019008109A (es) * 2017-01-06 2019-09-04 Servier Lab Combinacion de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmaceuticas de esta.
JP7186731B2 (ja) * 2017-06-22 2022-12-09 レ ラボラトワール セルヴィエ 血液ガンのためのmcl-1阻害剤と標準治療処置との組み合わせ、その使用及び医薬組成物
CN112739343A (zh) * 2017-08-15 2021-04-30 艾伯维公司 大环mcl-1抑制剂和使用方法
SG10202106345VA (en) 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
WO2019101144A1 (zh) * 2017-11-23 2019-05-31 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
TW202038960A (zh) 2018-11-14 2020-11-01 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
EA202191534A1 (ru) * 2018-12-06 2021-10-27 Ле Лаборатуар Сервье Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
US20230081720A1 (en) 2019-05-20 2023-03-16 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
EP4038072A4 (en) * 2019-10-03 2023-08-02 California Institute Of Technology MCL1 INHIBITORS AND USES THEREOF
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CA3222269A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
CN113651663B (zh) * 2021-08-20 2024-03-29 浙大宁波理工学院 一种氘代芳香羰基类化合物的制备方法
WO2023057484A1 (en) 2021-10-06 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
NZ546044A (en) * 2003-08-29 2009-09-25 Vernalis Cambridge Ltd Pyrimidothiophene compounds
TWI438205B (zh) * 2008-03-05 2014-05-21 Methylgene Inc 蛋白質酪胺酸激酶活性抑制劑
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
JP6741697B2 (ja) 2020-08-19
US10227358B2 (en) 2019-03-12
FR3037957A1 (es) 2016-12-30
WO2016207225A1 (en) 2016-12-29
CA2990088A1 (en) 2016-12-29
GEP20207074B (en) 2020-03-10
EP3313851B1 (en) 2019-11-06
JO3675B1 (ar) 2020-08-27
SI3313851T1 (sl) 2020-03-31
AU2016282836B2 (en) 2020-07-09
EA201890125A1 (ru) 2018-06-29
UA122228C2 (uk) 2020-10-12
UY36736A (es) 2016-12-30
NZ738455A (en) 2024-03-22
HRP20200107T1 (hr) 2020-04-03
BR112017027414A2 (pt) 2018-08-28
AR105103A1 (es) 2017-09-06
JP2018522855A (ja) 2018-08-16
MA42239B1 (fr) 2020-02-28
RS59904B1 (sr) 2020-03-31
KR20180019223A (ko) 2018-02-23
DK3313851T3 (da) 2020-01-27
PH12017502246A1 (en) 2018-05-28
EA033266B1 (ru) 2019-09-30
US20180170947A1 (en) 2018-06-21
HUE047889T2 (hu) 2020-05-28
ES2759480T3 (es) 2020-05-11
CL2017003258A1 (es) 2018-06-01
CY1122542T1 (el) 2021-01-27
CO2017012786A2 (es) 2018-04-10
BR112017027414B1 (pt) 2023-12-19
CR20170564A (es) 2018-02-20
RU2018102365A3 (es) 2019-09-23
RU2018102365A (ru) 2019-07-23
CN107709333A (zh) 2018-02-16
MX2017016997A (es) 2018-09-07
PT3313851T (pt) 2020-01-06
RU2734418C2 (ru) 2020-10-16
US10711010B2 (en) 2020-07-14
CA2990088C (en) 2021-04-13
EP3313851A1 (en) 2018-05-02
FR3037957B1 (fr) 2019-01-25
TW201709911A (zh) 2017-03-16
HK1254657A1 (zh) 2019-07-26
PL3313851T3 (pl) 2020-05-18
CN107709333B (zh) 2021-01-01
IL256270A (en) 2018-02-28
PE20180742A1 (es) 2018-04-27
MD3313851T2 (ro) 2020-02-29
MY190561A (en) 2022-04-27
HK1249506A1 (zh) 2018-11-02
ECSP17081744A (es) 2018-02-28
PH12017502246B1 (en) 2018-05-28
ZA201708460B (en) 2021-06-30
TN2017000511A1 (en) 2019-04-12
CU20170160A7 (es) 2018-05-08
AU2016282836A1 (en) 2018-01-18
US20190161496A1 (en) 2019-05-30
TWI604844B (zh) 2017-11-11

Similar Documents

Publication Publication Date Title
SV2017005587A (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen
SV2017005589A (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen
SV2017005590A (es) Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen
SV2018005722A (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
SV2017005588A (es) Nuevos derivados aminoacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen
SV2018005791A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2018005792A (es) Nuevos derivados piperidinilo sustituidos con hetero (arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201600016A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los continen.
SV2014004879A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen